India Clinical Trials Market to grow at a Significant Rate During the Forecast Period
Rising prevalence of chronic
conditions is expected to drive the growth of India clinical trials market
during the forecast period.
According
to TechSci Research report, “India Clinical Trials Market By Phase (Phase I,
Phase II, Phase III, Phase IV), By Study Design (Interventional, Treatment
Studies, Observational, Expanded Access), By Indication (Autoimmune, Blood
Disorders, Pain Management, Oncology, CNS Condition, Diabetes, Obesity,
Cardiovascular, Others), By End User (Hospital, Laboratories, Clinics), By
Company, By Region, Forecast & Opportunities, FY2026”, the India clinical trials market is expected to grow at a
steady rate during the forecast period. Increasing demand for clinical trials in
the country is projected to act as major market driving factor. Moreover, growing
number of biologics coupled with increasing need for personalized medicines are
further expected to fuel the market growth through FY2026. Furthermore, huge and
diverse population of India with chronic diseases is estimated to boost India
clinical trials market growth because of which different types of trials can be
conducted in one region. Thereby, helping in faster recruitment of the patients
and companies to conduct the trials on the timely basis.
Browse XX market data Tables and XX Figures spread
through XXX Pages and an
in-depth TOC on " India Clinical Trials
Market"
https://www.techsciresearch.com/report/india-clinical-trials-market/7239.html
The India clinical trials market is segmented based on phase, study
design, indication, place of conduct, company, and region. Based on indication,
the market can be fragmented into Autoimmune, Blood Disorders, Pain Management,
Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others. Out of
which, the oncology segment is projected to account for largest share in the
market which can be accredited to the high spending towards preclinical and
clinical development of oncology therapy products by the pharmaceutical
industry. The cardiovascular condition segment is projected to register fastest
growth over the forecast period on account of surging incidence of
cardiovascular diseases and increased demand for cost-effective medication in
the country. In terms of study design, the market is categorized into Interventional,
Treatment Studies, Observational, Expanded Access. The interventional design
segment dominated the market with largest revenue share until FY2020 as it is
one of the most prominent methods which is used in clinical trials. Besides, expanded
access trials segment is estimated to witness the fastest growing CAGR during
the forecast period owing to rising innovation in clinical trial methods. In
addition to this, it is a potential pathway for the patients dealing with
serious disease conditions so that it is possible to carry out treatment
outside the trial when no satisfactory therapies are available.
Pfizer India Ltd., Ѕun
Рhаrmасеutісаl Іnduѕtrіеѕ Ltd., GlaxoSmithKline Pharmaceuticals Ltd., IQVIA
India Pvt. Ltd., Covance Ltd., Ноffmаnn-Lа Rосhе India Ltd., Novartis India
Ltd., AstraZeneca India Pvt. Limited, Pharmaceutical Product Development Ltd.,
Eli Lilly and Company (India) Pvt. Ltd and others are
some of the leading players operating in India clinical trials market.
Companies operating in the market are using organic strategies such as collaborations
with hospitals in order to conduct their clinical trials.
Download
Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7239
Customers can also
request for 10% free customization on this report.
“India clinical trials market is expected
to witness steady growth during the forecast period on account of surging
requirement for new medicines as well as medical equipment amongst the
healthcare providers. Along with this, growing investments in drug development
activities by major market players operating in the market is further
forecasted to bode well for the growth of clinical trials market in the country.
Moreover, continuous initiatives by the government of the country for the
promotion of drug discovery is further expected to create lucrative
opportunities for the market growth of India clinical trials market over the
next five years.” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based India management consulting firm.
“India Clinical Trials Market By Phase (Phase I,
Phase II, Phase III, Phase IV), By Study Design (Interventional, Treatment
Studies, Observational, Expanded Access), By Indication (Autoimmune, Blood
Disorders, Pain Management, Oncology, CNS Condition, Diabetes, Obesity,
Cardiovascular, Others), By Place of Conduct (Hospital, Laboratories, Clinics,
Others), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India clinical
trials market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in India clinical trials market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]